TAK-041
- Generic Name
- TAK-041
Neurocrine Biosciences Gains Exclusive Rights to Osavampator for Depression Treatment Outside Japan
• Neurocrine Biosciences amended its agreement with Takeda to obtain exclusive worldwide rights to develop and commercialize osavampator for major depressive disorder (MDD), excluding Japan.
• Osavampator (NBI-1065845) demonstrated statistically significant improvements in depression symptoms in a Phase 2 trial, meeting primary and key secondary endpoints.
• Neurocrine plans to initiate a Phase 3 program for osavampator in the first half of 2025, following a successful End-of-Phase 2 meeting with the FDA.
• Takeda reacquired exclusive rights for osavampator in Japan and will be responsible for development costs in its region, while both companies are eligible for royalty payments.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath